Significant Improvements in Psoriatic Arthritis With Ustekinumab: Research

New PSUMMIT 2* data further demonstrate the efficacy of ustekinumab in Psoriatic Arthritis (PsA). The data was first presented at EULAR 2013.

New PSUMMIT 2* data further demonstrate the efficacy of ustekinumab in Psoriatic Arthritis (PsA). The data was first presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism.

Anti-TNF naïve and anti-TNF-experienced patients randomised to one of two ustekinumab doses (45mg or 90mg) demonstrated significant and sustained improvements in the signs and symptoms of PsA, with favourable safety profiles.

Bursitis / Inflammation of the Bursa
Bursitis is the inflammation of the bursa, which is a fluid-filled sac that reduces friction during joint movement.

PsA is a chronic inflammatory arthritis associated with psoriasis which significantly impacts health-related quality of life and function in patients, and increases risk of co-morbid cardiovascular and gastrointestinal diseases.2 Prevalence of psoriasis varies from 0.3% to 3% of the population, with PsA occurring in 25% of cases.3

Lead author of the study Dr Christopher Ritchlin, University of Rochester Medical Centre, Rochester, US, commented "While the development of anti-TNF treatments has drastically improved the treatment of PsA, there are still substantial numbers of patients who fail to respond to therapy. That ustekinumab demonstrates improvements not just in anti-TNF-naïve patients, but in those who have been treated with one or more drugs, shows that it has the potential to fulfil a significant unmet patient need."

312 adults with active PsA were randomised to ustekinumab 45mg or 90mg (week 0, week 4 and every 12 weeks subsequent to Week 40) or placebo (week 0, week 4 and week 16) followed by crossover to ustekinumab 45mg (week 24, week 28 and week 40). The primary endpoint was ACR20† at week 24; secondary endpoints were HAQ-DI, ACR50, ACR70 and >75% improvement in the Psoriasis Area and Severity Index (PAS175).‡

Oligoarthritis | Children and Arthritis - Types, Diagnosis, Treatment
Most parents when told that their child has arthritis find it hard to believe it, as arthritis is regarded an adult's disease.

Anti-TNF-experienced patients in PSUMMIT 2 had more active disease at baseline than anti-TNF naïve. At week 24, more patients treated with ustekinumab than placebo had achieved ACR20 (combined 43.8%; 45mg 43.7%; 90mg 43.8%; placebo 20.2% – all p>0.001). Efficacy was sustained at week 52, with patients on 45mg, 90mg and placebo-ustekinumab reaching ACR20 (46.8%, 48.4% and 55.8% respectively).

Efficacy demonstrated was more robust in anti-TNF-naïve (ACR 20 59-73%) than anti-TNF-experienced (37-41%) patients, and patients who had previously received one (50-55%) vs. two (13-39%) or three or more (13-30%) agents.

Guidelines for Psoriatic Arthritis Treatment
A group of rheumatologists, dermatologists, and patient advocates has published the first-ever international guidelines for the treatment of psoriatic arthritis, a disease that mainly

Ustekinumab was well tolerated with no deaths or TB and similar rates of adverse events (45mg 78.6%; 90mg 77.9%), serious adverse events (45mg 5.8%, 90mg 5.8%) and adverse events leading to discontinuation (45mg 5.8%, 90mg 3.8%) reported through to week 60.

Source-Eurekalert

Psoriatic Arthritis Suffers Have Vitamin D Insufficiency
A high prevalence of vitamin D insufficiency and deficiency among patients with psoriatic arthritis has been identified in a new research.